(Q33914374)

30 July 2017

1 reference

title

Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease (English)

1 reference

30 July 2017

0 references

1 reference

2

A Markham

0 references

author name string

D Clemett

series ordinal

1

1 reference

30 July 2017

A Markham

series ordinal

2

1 reference

30 July 2017

publication date

1 April 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

59

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

929-956

1 reference

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

Mechanism of action of 5-aminosalicylic acid and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

Mesalazine-associated interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

New developments in the pharmacotherapy of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200059040-00016

Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease

21 January 2018

1 reference

12 December 2020

Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.

1 reference

12 December 2020

Epidemiology of inflammatory bowel disease: an update

1 reference

12 December 2020

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

1 reference

12 December 2020

Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis

1 reference

12 December 2020

Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis

1 reference

12 December 2020

Second trial of mesalamine therapy in the treatment of active Crohn's disease

1 reference

12 December 2020

Chronic interstitial nephritis and mesalazine: 3 new cases?

1 reference

12 December 2020

Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases

1 reference

12 December 2020

5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells.

1 reference

12 December 2020

Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis

1 reference

12 December 2020

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

12 December 2020

Test of an instrument to measure function-related quality of life in patients with ulcerative colitis

1 reference

12 December 2020

Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease

1 reference

12 December 2020

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

1 reference

12 December 2020

Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease

1 reference

12 December 2020

Delivery and fate of oral mesalamine microgranules within the human small intestine

1 reference

12 December 2020

Renal and urologic complications of inflammatory bowel disease

1 reference

12 December 2020

Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis

1 reference

12 December 2020

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

12 December 2020

Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease

1 reference

12 December 2020

Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn's disease

1 reference

12 December 2020

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

1 reference

12 December 2020

Pentasa in lieu of sulfasalazine

1 reference

12 December 2020

Management of Crohn's disease in adults

1 reference

12 December 2020

Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine

1 reference

12 December 2020

Quantification of distinct molecular species of platelet activating factor in ulcerative colitis

1 reference

12 December 2020

Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4.

1 reference

12 December 2020

Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.

1 reference

12 December 2020

Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease

1 reference

12 December 2020

Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation

1 reference

12 December 2020

Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease

1 reference

12 December 2020

Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease

1 reference

12 December 2020

Management of inflammatory bowel disease

1 reference

12 December 2020

Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis

1 reference

12 December 2020

[Exanthema in 2 patients with ulcerative colitis treated with Pentasa]

1 reference

12 December 2020

Side-effects of salazopyrin on male fertility

1 reference

12 December 2020

Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee.

1 reference

12 December 2020

Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation

1 reference

12 December 2020

Mesalazine induced exacerbation of ulcerative colitis

1 reference

12 December 2020

New therapeutic agents in the treatment of inflammatory bowel disease

1 reference

12 December 2020

Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis

1 reference

12 December 2020

Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine?

1 reference

12 December 2020

Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet

1 reference

12 December 2020

A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

12 December 2020

Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis

1 reference

12 December 2020

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

12 December 2020

Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid

1 reference

12 December 2020

Incidence of sulphasalazine-induced male infertility

1 reference

12 December 2020

Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation

1 reference

12 December 2020

Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

1 reference

12 December 2020

5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans

1 reference

12 December 2020

Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine

1 reference

12 December 2020

Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects

1 reference

12 December 2020

Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.

1 reference

12 December 2020

Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules

1 reference

12 December 2020

[Pregnancy outcome in inflammatory bowel diseases]

1 reference

12 December 2020

Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon

1 reference

12 December 2020

Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease

1 reference

12 December 2020

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease

1 reference

12 December 2020

[Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease]

1 reference

12 December 2020

Excessive production of reactive oxygen metabolites by inflamed colon: Analysis by chemiluminescence probe

1 reference

12 December 2020

Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update

1 reference

12 December 2020

Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man

1 reference

12 December 2020

Predictability of the postoperative course of Crohn's disease

1 reference

12 December 2020

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

1 reference

12 December 2020

Dissolution profiles of mesalazine formulations in vitro

1 reference

12 December 2020

5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?

1 reference

12 December 2020

Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy

1 reference

12 December 2020

Platelet-activating factor--a possible mediator in the pathogenesis of ulcerative colitis

1 reference

12 December 2020

Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations

1 reference

12 December 2020

5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa

1 reference

12 December 2020

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

12 December 2020

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

1 reference

12 December 2020

Guidelines for the treatment of ulcerative colitis in remission

1 reference

12 December 2020

Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus andper os slow-release formulation

1 reference

12 December 2020

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

1 reference

12 December 2020

[Iatrogenic diffuse interstitial pneumonia linked to 5-aminosalicylate]

1 reference

12 December 2020

Salicylates for ulcerative colitis--their mode of action

1 reference

12 December 2020

Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid

1 reference

12 December 2020

An experiment to determine the active therapeutic moiety of sulphasalazine

1 reference

12 December 2020

Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid

1 reference

12 December 2020

Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine

1 reference

12 December 2020

5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa

1 reference

12 December 2020

Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms

1 reference

12 December 2020

The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells

1 reference

12 December 2020

Inflammatory bowel disease

1 reference

12 December 2020

Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group

1 reference

12 December 2020

National Cooperative Crohn's Disease Study: adverse reactions to study drugs

1 reference

12 December 2020

Modulation of Arachidonic Acid Metabolism by Olsalazine and Other Aminosalicylates in Leukocytes

1 reference

12 December 2020

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

1 reference

12 December 2020

Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease

1 reference

12 December 2020

Induction of major histocompatibility complex class II antigens on human colonic epithelium by interferon-gamma, tumor necrosis factor-alpha, and interleukin-2

1 reference

12 December 2020

Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone

1 reference

12 December 2020

Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients

1 reference

12 December 2020

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

12 December 2020

Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones

1 reference

12 December 2020

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes

1 reference

12 December 2020

Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression

1 reference

12 December 2020

Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France

1 reference

12 December 2020

New salicylates as maintenance treatment in ulcerative colitis

1 reference

12 December 2020

A practical guide to the management of distal ulcerative colitis

1 reference

12 December 2020

Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.

1 reference

12 December 2020

5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon

1 reference

12 December 2020

Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease

1 reference

12 December 2020

Induction of HLA-DR antigen expression on human colonic epithelium by tumor necrosis factor-alpha and interferon-gamma

1 reference

12 December 2020

The oxygen-centered radicals scavenging activity of sulfasalazine and its metabolites. A direct protection of the bowel

1 reference

12 December 2020

Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

1 reference

12 December 2020

Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea

1 reference

12 December 2020

10.2165/00003495-200059040-00016

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1010018973

0 references

1 reference